Bio-Rad Labs (BIO) Misses Q3 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Bio-Rad Reports Third-Quarter 2018 Financial Results
November 1, 2018 4:30 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2018.
Third-quarter 2018 net sales were $545.1 million, an increase of 2.1 percent compared to $534.1 million reported for the third quarter of 2017. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2017, reflecting growth across the business. Third-quarter gross margin was 52.6 percent compared to 56.0 percent during the third quarter in 2017. Gross margin in the third quarter of 2018 was impacted by higher costs for service, warranty... More
